Roche’s Gazyva adds 3rd immune indication with first FDA nod for primary membranous nephropathy

Roche
In primary membranous nephropathy, Gazyva convinced the FDA with phase 3 data showing it was better than the immunosuppressant tacrolimus at reducing proteinuria. (Photo via Smith Collection/Gado/Getty Images)

As Roche’s Gazyva comes under pressure in blood cancer, the anti-CD20 antibody keeps expanding its reach in autoimmune diseases.

In its third U.S. indication for an immune-mediated condition, Gazyva has become the first FDA-approved treatment for primary membranous nephropathy (pMN), a rare disease where the immune system mistakenly attacks the tiny filtering units in the kidneys.

The drug is specifically approved to reduce proteinuria, or the abnormal presence of protein in the urine, which is a key indicator of kidney damage.

“pMN can lead to debilitating physical and psychological symptoms that place a heavy burden on patients, families and healthcare systems alike,” Teresa Graham, CEO of Roche Pharmaceuticals, said in a Nov. 16 statement. “This first-ever FDA approval delivers an important targeted treatment option for the pMN community and expands how many people may benefit from Gazyva across multiple severe immune-mediated kidney diseases.”

Besides pMN, Gazyva is also cleared for certain blood cancers, active lupus nephritis and idiopathic nephrotic syndrome, and it’s awaiting an FDA decision by Dec. 4 for what could be its fourth immune indication, systemic lupus erythematosus.

In pMN, Gazyva convinced regulators with results from the phase 3 Majesty trial showing it was better than the immunosuppressant tacrolimus at reducing proteinuria. At two years, 36.1% of patients who took Gazyva achieved complete remission of proteinuria, versus 5.7% with tacrolimus.  Complete remission was defined as a urine protein-creatinine ratio of no more than 0.3 g/g with a stable estimated glomerular filtration rate (eGFR) without any use of rescue therapy, treatment failure or early study discontinuation. 

Gazyva’s advantage over tacrolimus also sustained to week 76 with a 36.1% complete remission rate, versus 8.6% for the comparator group.

Roche has been looking to autoimmune diseases—beginning with a lupus nephritis nod a year ago—to fuel Gazyva’s growth, having tied 2 billion Swiss francs in peak sales projections to those indications. 

For now, Gazyva’s overall sales have been held back by fierce competition in chronic lymphocytic leukemia and follicular lymphoma. In the first nine months of 2026, the drug reached 751 million Swiss francs, signaling 7% growth year over year at constant exchange rates. 

Roche plans to separately report Gazyva’s sales by therapeutic area in the future.